Proactive Investors
12 Aug 2026, 06:38 UTC · 1h ago
CelLBxHealth's blood test spots hard-to-detect cells from brain tumours
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Proactive Investors
12 Aug 2026, 06:38 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
An independent study published in JCO Precision Oncology found that CelLBxHealth's Parsortix platform can isolate circulating tumour cells (CTCs) from the blood of glioblastoma patients. — Establishing a blood-based detection method for an aggressive brain cancer previously thought unlikely to spread to blood is a major technical breakthrough for the company.
+0.80The proposed detection threshold achieved 80% sensitivity and 77.3% specificity in distinguishing glioblastoma patients from healthy controls. — These quantitative performance metrics provide a tangible basis for the clinical viability and future commercial potential of the diagnostic tool.
+0.60The technology successfully distinguished between returning tumours and radionecrosis (radiation damage), a task that traditional imaging scans often struggle to perform. — Solving a specific clinical pain point (treatment effect vs. recurrence) increases the likelihood of adoption by clinicians.
+0.50Continue reading
6 related stories
Top 1 mover · tap to explore
The blood-borne cells captured by the platform reflected the same tumour-related mutations and chromosomal changes as matched invasive tissue samples. — Validation against the gold standard (tissue biopsy) proves the biological accuracy of the liquid biopsy approach.
+0.40Which stocks this story touches
An independent study showed its Parsortix platform can effectively capture and analyze tumor cells from patients with aggressive brain cancer.
Mentioned as having dosed its first US patient, indicating positive clinical progress.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
17h ago
